By Vera, Vocemundi · 2026-11-18
The White House has withdrawn its nomination of Heidi Overton to lead the US Food and Drug Administration (FDA). A White House official told the Guardian. STAT News reported the withdrawal, citing a White House official and a source close to Overton.
The Senate health committee had been scheduled to vote on the nomination on Wednesday, the day after the withdrawal. Sen. Bill Cassidy (R-La.) leads that committee.
Overton is a physician. STAT News describes her as a preventive care doctor. According to STAT News, she previously served in the Trump White House. The Guardian reports that Donald Trump nominated her in August and describes her as a prominent abortion opponent.
After the withdrawal, Cassidy criticised the decision in a post on X. "Tonight, the White House abandoned a viable confirmation path for Dr. Overton," he wrote, according to both outlets.
Earlier that day, Cassidy said he remained undecided about the nomination, according to the Guardian.
Possible replacement
The White House is considering nominating Sen. Roger Marshall of Kansas to lead the FDA, according to the Guardian. The Guardian attributed this to Reuters, which cited two people familiar with the matter. The Guardian reports that Marshall is an OB/GYN who previously served in the House of Representatives. He sits on the Senate health committee and opposes abortion. He is finishing his Senate term after losing his reelection bid. The Guardian's account of the Reuters report is incomplete.
According to the Guardian, Democrats are due to take the Senate majority in the new year.
What is disputed
The accounts differ on whether Overton had enough support. STAT News reported that the decision followed concerns that she lacked sufficient support from Republicans on the health panel. Cassidy said she would have passed both the committee and the full Senate.
The reason for the withdrawal is also contested. According to Cassidy, the White House said she did not have the votes. Cassidy said the final issue was that pro-life senators had sought assurances from the administration on its commitment to life issues.
What each side says
Cassidy called the White House's stated reason odd. The Guardian quoted him as saying: "The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members." He added: "I believe she would have had the votes to pass out of committee and pass the full Senate."
He also said: "The Administration withdrew Dr. Overton rather than make such commitments. Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats."
The reports reviewed by Vocemundi do not include an on-record White House statement explaining the withdrawal. Its stated reason appears only as Cassidy described it. The reports do not include any response from Overton. Apart from Cassidy, whom the Guardian reported as undecided earlier in the day, they do not name senators who were opposed or undecided, nor the pro-life senators who sought assurances, or the specific assurances sought beyond a commitment to life issues. They also do not say who leads the FDA in the interim.
Analysis
The withdrawal leaves the FDA without a confirmed nominee as the Senate's composition is due to change. Two explanations are on the table: insufficient votes, as Cassidy says the White House stated, or a dispute over assurances on abortion-related issues, as Cassidy describes. Without an on-record White House account, neither can be confirmed. If the administration does pursue a new nominee, such as Sen. Roger Marshall as Reuters reported, timing could matter. Cassidy has said a permanent commissioner's confirmation will fall to Senate Democrats. Whether that happens depends on decisions not yet described in the reports.
Produced by the Vocemundi newsroom with AI assistance.
This story was originally published by Vocemundi and is republished under a CC BY-NC-ND 4.0 license. How we verified this story.
